ATE165008T1 - Methode zur behandlung intestinaler krankheiten - Google Patents

Methode zur behandlung intestinaler krankheiten

Info

Publication number
ATE165008T1
ATE165008T1 AT91903465T AT91903465T ATE165008T1 AT E165008 T1 ATE165008 T1 AT E165008T1 AT 91903465 T AT91903465 T AT 91903465T AT 91903465 T AT91903465 T AT 91903465T AT E165008 T1 ATE165008 T1 AT E165008T1
Authority
AT
Austria
Prior art keywords
intestinal diseases
treating intestinal
igf
disorders
patient
Prior art date
Application number
AT91903465T
Other languages
English (en)
Inventor
Francis John Ballard
Leanna Christine Read
Original Assignee
Gropep Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3774495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE165008(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gropep Pty Ltd filed Critical Gropep Pty Ltd
Application granted granted Critical
Publication of ATE165008T1 publication Critical patent/ATE165008T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
AT91903465T 1990-02-13 1991-01-30 Methode zur behandlung intestinaler krankheiten ATE165008T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ858690 1990-02-13

Publications (1)

Publication Number Publication Date
ATE165008T1 true ATE165008T1 (de) 1998-05-15

Family

ID=3774495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91903465T ATE165008T1 (de) 1990-02-13 1991-01-30 Methode zur behandlung intestinaler krankheiten

Country Status (5)

Country Link
EP (1) EP0515434B1 (de)
AT (1) ATE165008T1 (de)
CA (1) CA2074166C (de)
DE (1) DE69129267T2 (de)
WO (1) WO1991012018A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234439A (en) * 1990-07-10 1997-08-22 Pharmacia & Upjohn Ab Use of igf-1 to reduce fetal growth retardation in non human mammals
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
JPH06510065A (ja) * 1992-06-08 1994-11-10 カイロン　コーポレーション 成長因子ｉｇｆ−ｉおよび／またはｉｇｆ−ｉｉの用法
NZ260309A (en) * 1992-06-08 1997-07-27 Pharmacia Ab Substituted For K Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
AU5863396A (en) * 1995-06-02 1996-12-18 Harbor-Ucla Research And Education Institute Insulin suppression test with igf
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
ATE463252T1 (de) 2000-08-29 2010-04-15 Aurogen Inc Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
US8026211B2 (en) * 2004-06-02 2011-09-27 Technion Research & Development Foundation Ltd. Methods and formulations for increasing intestinal function
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
EP0346429B1 (de) * 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2)
CA2033176C (en) * 1989-06-09 1999-12-14 Julian Richard Este Wells Growth hormone fusion proteins
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor

Also Published As

Publication number Publication date
DE69129267T2 (de) 1998-09-10
EP0515434B1 (de) 1998-04-15
EP0515434A4 (en) 1993-06-16
WO1991012018A1 (en) 1991-08-22
CA2074166A1 (en) 1991-08-14
DE69129267D1 (de) 1998-05-20
EP0515434A1 (de) 1992-12-02
CA2074166C (en) 2003-11-25

Similar Documents

Publication Publication Date Title
DE69324117D1 (de) Verfahren zur Behandlung von Knochengeweben und implantierbare Biomaterialien dafür
DE69129267D1 (de) Methode zur behandlung intestinaler krankheiten
ATE136753T1 (de) Methode zur beseitigung von infektionserregern in geweben
ATE419014T1 (de) Verbindungen zur behandlung der ischaemischen gewebe
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69322957D1 (de) L - Deprenyl zur Behandlung von makulärer Degeneration
DE69025922D1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
ATE116550T1 (de) Behandlung von neoplastischen krankenheiten mit interleukin-10.
ATE260107T1 (de) Debromhymenialdisin und verwandte verbindungen zur behandlung von osteoarthritis
DE3786893D1 (de) Piperidinderivat zur schmerzbehandlung.
DE3483931D1 (de) Wachstumshormone freisetzende peptiden und methode fuer die behandlung von saeugetieren.
ATE377026T1 (de) Behandlung von fettleibigkeit
NO975360D0 (no) Peptid som inhiberer forhöyede triglyceridnivåer i blod og midler som inneholder nevnte peptid som aktiv komponent
ATE454451T1 (de) Methode zur behandlung von muskelkrankheiten
DE3685853D1 (de) Mittel zur behandlung von knochenkrankheiten.
ATE138587T1 (de) Einrichtung zur medizinischen behandlung
ATE183651T1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
RU93058185A (ru) Фактор роста, композиция, способ модулирования действий фактора, способ лечения, способ доставки соединения, способы анализа
ATE22659T1 (de) Verfahren zur behandlung der azyklie bei schafen oder rindern.
ATE246511T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndroms
DE69133074D1 (de) Einen basischen Fibroblastwachstumsfaktor enthaltende Mittel zur Behandlung von Knochenkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties